AIDS 2022

AIDS 2022
July 29-August 02, 2022
Montreal, Canada, and virtually

The 24th International AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Results (14)

Real-world utilization of HIV pre-exposure prophylaxis (PrEP) by cisgender and transgender individuals in the United States

Concordance between laboratory serologic testing and HIV-1 RNA testing among participants who acquired HIV in the DISCOVER trial

Lipid parameters and lipid-modifying agent use in participants initiating F/TAF or F/TDF for PrEP in the DISCOVER trial

Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus phase 2/3 regimen

Flt3 agonist enhances immunogenicity of arenavirus-based vaccine vector in macaques

Week 48 results of a phase 3 randomized controlled trial of B/F/TAF vs DTG + F/TDF as initial treatment in adults with HIV/HBV coinfection (ALLIANCE)

Metabolomic and lipidomic correlates of time-to-HIV-rebound in viremic controllers treated with vesatolimod

Impact of intrinsic and extrinsic factors on the pharmacokinetics of long-acting lenacapavir for treatment of HIV

Longitudinal analysis of weight change in HIV-1 treatment-naïve and -experienced people living with HIV (PLWH) initiating/switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies

Resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 54 weeks

Simulations for once-weekly dosing of oral lenacapavir

Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-up

Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 52 weeks of treatment

Injection-site reaction experience in clinical studies of people using lenacapavir for HIV treatment